Yichang Renfu Pharmaceuticals Approved to Market Micafungin Sodium for Injection
Time：
2024-06-17
Recently, Yichang Renfu Pharmaceutical Company received the Certificate of Registration of Drugs approved and issued by the State Drug Administration, approving the listing of Micafungin Sodium for Injection.
Recently, Yichang Renfu Pharmaceutical Company received the Certificate of Registration of Drugs approved and issued by the State Drug Administration, approving the listing of Micafungin Sodium for Injection.
Micafungin sodium is a new type of echinocandin antifungal drug, mainly by inhibiting the synthesis of 1,3-β-D-glucan, the main component of the fungal cell wall, thus destroying the synthesis of the fungal cell wall, affecting the cell morphology and osmotic pressure, leading to the death of cell lysis. Micafungin sodium for injection is indicated for the following infections caused by Aspergillus and Candida: fungemia, respiratory mycoses, gastrointestinal mycoses. This kind of drug has low toxicity to human body, and is characterized by wide antimicrobial spectrum, long half-life and good patient tolerance.
The product will provide a new choice for domestic anti-infective clinical treatment after listing, and the company will subsequently actively promote the relevant work after the listing of Micafungin Sodium for Injection.
Tags:
Related News
INTERMEDIATES
ABOUT US
CONTACT
Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888
E-mail：yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.